What tools do men need to make an informed decision about germline genetic testing for prostate cancer: A qualitative and survey study

This qualitative and survey study identifies critical knowledge gaps and concerns regarding germline genetic testing for prostate cancer, such as family risk and insurance discrimination, and demonstrates the development of a patient-centered information toolkit to address these needs while highlighting the necessity for further testing across diverse contexts.

The Gist

Imagine you've just been told you have prostate cancer. Now, imagine someone hands you a map to a treasure hunt, but the map is written in a secret code, the terrain is unfamiliar, and you're worried that if you follow the map, your insurance company might raise your rates or your family might get hurt.

This paper is about a team of researchers in Tasmania who wanted to help men navigate that confusing map. They asked: "What tools do men actually need to make a smart decision about genetic testing for prostate cancer?"

Here is the story of their journey, broken down into simple parts.

The Big Picture: Why This Matters

Prostate cancer is the most common cancer in men, and it runs in families more than almost any other cancer. Think of your DNA like a library of books. Sometimes, there's a typo in one of those books (a gene mutation) that makes the cancer more dangerous or tells doctors which "medicine key" fits the "lock" of the cancer.

Finding these typos (genetic testing) is like having a GPS for your treatment. It can tell doctors exactly which drug will work best and warn your sons or brothers if they are at risk. But right now, most men don't have this GPS, and many don't even know it exists.

Phase 1: Listening to the Men (The Focus Groups)

The researchers gathered 20 men who had already beaten or were fighting prostate cancer. They sat them down in a circle (like a campfire chat) and asked, "What do you know? What do you want? What scares you?"

What they found:

• The Vocabulary Wall: Most men had heard the words "Precision Medicine" and "Genetic Testing," but they didn't really know what they meant. It was like hearing someone talk about "cloud computing" without knowing what a cloud is.
• The Superpower: The men who did understand were excited. They saw it as a way to get a "custom-made" treatment that would kill the cancer without the nasty side effects of the old, blunt-force methods.
• The Family Shield: The biggest reason men wanted to get tested wasn't for themselves—it was for their families. They wanted to be the guardian who warns their sons or brothers, "Hey, check your own DNA, just in case."
• The Big Fear: The scariest thing wasn't the cancer; it was insurance. Men were terrified that if they took a test and found a "bad gene," life insurance companies would say, "Nope, you're too risky, we won't cover you." (Even though the rules are changing, the fear was real).
• The "What If" Anxiety: Some men were worried, "If I find out I have a bad gene, will I have to tell my whole family? What if it causes them panic?"

Phase 2: Building the Toolkit (The Instruction Manual)

Based on those chats, the researchers built a User Manual (called an Information Toolkit). It was designed to explain genetic testing in plain English, covering costs, risks, and benefits.

Then, they showed this manual to three groups:

1. The Patients (the men with cancer).
2. The Family (wives, sons, daughters).
3. The Doctors (urologists, nurses, geneticists).

The Results of the Test Drive:

• The Doctors and Family said: "This is great! It's clear, it's helpful, and it explains the medical jargon." They looked at it like a technical manual for a car engine.
• The Patients said: "I'm not sure what this is for me right now." They looked at it like a map for a trip they haven't started yet. Because they had already been diagnosed and treated, they struggled to imagine how this tool would help them before they got sick or right when they were first diagnosed.
• The Confusion Points: Even in the "simple" manual, words like "Panel" (a group of genes tested at once) and "PARP" (a specific type of drug) were still confusing. It's like a mechanic saying, "You need a new carburetor," when you just want to know, "Will my car start?"
• Missing Pieces: The patients said, "You didn't tell us how much it costs!" and "You didn't tell us if our insurance will hate us!" They wanted real stories from other guys who had been through it, not just facts.

The Main Lesson: The "One-Size-Fits-All" Trap

The researchers realized a big mistake in their design. They built one toolkit for everyone, but everyone needs a different kind of help.

• Doctors want the technical specs (the engine details).
• Families want the practical facts (the safety features).
• Patients want the emotional connection (the story of the journey).

The paper concludes that to help men make a decision, we can't just hand them a brochure full of facts. We need to:

1. Tell Stories: Use real-life examples so men can see themselves in the story.
2. Address the Fears: Be very clear about insurance laws and privacy so the fear of "getting in trouble" goes away.
3. Speak Human: Ditch the confusing medical words. If you say "Panel," explain it means "a list of genes we check together."
4. Timing is Everything: This information needs to be given before the diagnosis or right at the start, not after the treatment is over.

The Bottom Line

This study is like a compass check. The researchers found that while the technology for genetic testing is amazing, the tools we give to patients to understand it are broken.

To fix this, we need to stop talking at patients and start talking with them. We need to build a toolkit that feels less like a medical textbook and more like a friendly guide from a buddy who has walked the path before, ready to say, "Here's what you need to know, here's what to watch out for, and here's how you can protect your family."

Technical Summary

1. Problem Statement

Prostate cancer (PrCa) is the most heritable common cancer, yet the integration of germline genetic testing into clinical care in Australia (and globally) lags significantly behind other cancers like breast and ovarian cancer.

• Equity Gaps: Access to precision medicine and genetic services is disproportionately poor for men in regional, rural, and remote areas, leading to later diagnoses and worse outcomes.
• Knowledge Deficits: There is a critical lack of patient understanding regarding "precision medicine" and the specific utility of germline testing for PrCa.
• Tooling Gap: While patient engagement is vital for healthcare design, no study has previously co-designed a PrCa-specific precision medicine information tool, particularly within a regional/rural context.
• Barriers: Patients face significant barriers including insurance discrimination fears, cost concerns, and anxiety regarding family implications, which hinder the uptake of beneficial genetic testing.

2. Methodology

The study employed a two-phase mixed-methods approach involving qualitative focus groups and quantitative surveys, approved by the University of Tasmania's Human Research Ethics Committee.

Phase I: Exploratory Qualitative Study

• Participants: 20 men previously diagnosed with PrCa (aged 50–83, average 72).
• Data Collection: Four focus groups (4–8 participants each) conducted between December 2022 and September 2023.
• Analysis: Focus groups were transcribed verbatim and analyzed thematically using NVivo. Saturation was achieved after four groups.
• Goal: To determine patient opinions, perceptions, expectations, and informational needs regarding germline genetic testing.

Phase II: Tool Development and Evaluation

• Intervention: A Precision Medicine in Prostate Cancer Information Toolkit was co-designed based on Phase I themes.
• Participants:
  • 14 patients (all from Phase I).
  • 4 carers/family members.
  • 14 healthcare providers (oncologists, urologists, nurses, geneticists, pathologists).
• Data Collection: Patients participated in two focus groups (June/July 2024); carers and providers completed an e-survey via RedCap.
• Analysis: Focus group transcripts were analyzed using Leximancer; survey data was manually coded in Excel. Themes were compared across groups to assess clarity, readability, and usefulness.

3. Key Contributions

• Co-Design Framework: The study provides a model for developing patient-centered information tools by actively engaging patients, carers, and clinicians in the iterative design process.
• Identification of Specific Knowledge Gaps: It highlights that while patients understand the concept of genetic testing generally, they lack specific knowledge regarding its application to PrCa, the definition of "precision medicine," and the distinction between somatic and germline testing.
• Addressing Insurance Literacy: The study uncovers a critical confusion between health and life insurance regarding genetic discrimination, noting that while health insurance cannot be denied based on genetic results in Australia, life insurance policies were a major source of fear (at the time of the study).
• Toolkit Iteration: The development and evaluation of a specific toolkit reveals that tools designed for patients often fail to resonate emotionally or practically if they do not address immediate lived-experience concerns (e.g., cost, family impact) rather than just clinical facts.

4. Key Results

Phase I Findings (Patient Perspectives):

• Knowledge: 9/20 had heard of "precision medicine" but few understood it. All had heard of genetic testing, but few understood its specific application to PrCa.
• Motivations: The primary driver for testing was informing family members' risk (n=7), followed by identifying effective treatment options (n=6).
• Concerns: The most significant barrier was insurance discrimination (n=5), specifically regarding life insurance. Other concerns included anxiety about decision-making and equity of access/cost.
• Information Needs: Patients requested simplified information on testing methods, treatment implications, costs, and data privacy. They preferred information from trusted clinicians (doctors or genetic counselors) and suggested male nurses as supportive figures.

Phase II Findings (Toolkit Evaluation):

• Clarity Discrepancy: Healthcare providers (8/14) and carers (4/4) found the toolkit's purpose clear, whereas only 5/14 patients felt the same. Patients struggled to imagine the toolkit's utility at the time of diagnosis.
• Terminology Barriers: While medical terms were generally well-defined, specific jargon like "panel" and "PARP" (Poly (ADP-ribose) polymerase) caused confusion among patients and carers.
• Missing Content:
  • Patients wanted details on: Cost, risk, test availability, PARP eligibility, insurance implications, timing in the cancer journey, and real patient stories.
  • Providers wanted details on: Consent/privacy, test procedures, MBS rebates, and specific genes included.
• Emotional Resonance: Patients found the toolkit lacked emotional relevance. They expressed that without real-life narratives, the information felt abstract and difficult to apply to their personal situation.

5. Significance and Implications

• Patient-Centered Care: The study demonstrates that effective health communication tools must move beyond clinical accuracy to address emotional resonance and lived experience. Tools that work for clinicians or carers often fail for patients if they do not include narrative elements (patient stories) to contextualize complex data.
• Policy and Practice: The findings underscore the urgent need to address insurance literacy and clarify legal protections against genetic discrimination to reduce patient anxiety.
• Future Directions:
  • The toolkit requires a second iteration to include patient narratives, clarify technical jargon (e.g., PARP, panels), and explicitly address cost and insurance concerns.
  • Future research should target men with recent diagnoses and those with family histories but no diagnosis to capture the decision-making process earlier in the care pathway.
  • The study highlights the necessity of tailored resources for regional/rural populations to reduce disparities in precision medicine access.

Conclusion:
This study reveals that while germline genetic testing is crucial for PrCa management, significant barriers exist regarding patient understanding and trust. A co-designed toolkit is a promising intervention, but its success depends on framing information around the patient's immediate practical and emotional concerns, rather than just clinical utility.